| Jul 17 |
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
|
| Jun 14 |
Biggest stock movers today: ADBE, MSM, RH, and more
|
| Jun 14 |
Ultragenyx Pharmaceutical prices $350 million securities offering
|
| Jun 14 |
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
|
| Jun 13 |
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
|
| Jun 13 |
Increases to CEO Compensation Might Be Put On Hold For Now at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
|
| Jun 13 |
Insider Sale: EVP and Chief Legal Officer Karah Parschauer Sells Shares of Ultragenyx ...
|
| Jun 12 |
Ultragenyx to file for accelerated approval of rare metabolic disease candidate
|
| Jun 12 |
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
|
| Jun 12 |
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
|
